Hospira enters angry-investor phase of remediation

Hospira ($HSP) shareholders claim the company didn't disclose the extent of problems at its North Carolina plant. Yet CEO Michael Ball admitted in October 2011 that the remediation job was "bigger than we thought." Nonetheless, the ailing generics-maker is now dealing with class action lawsuits over what it didn't mention about GMP problems while crowing about its efficiency and cost-cutting program. Hospira is in good company: Johnson & Johnson ($JNJ), Genzyme and Caraco each faced investor lawsuits along their remediation journeys. Story

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.